

February 22, 2023

Via EDGAR

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Jason Drory

**Re: VectivBio Holding AG**  
**Registration Statement on Form F-3**  
**Filed January 27, 2023**  
**File No. 333-269450**

Acceleration Request

Requested Date: February 24, 2023

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “**Registrant**”) hereby requests that the Securities and Exchange Commission (the “**Commission**”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-269450) (the “**Registration Statement**”), to become effective on February 24, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commission’s staff. The Registrant hereby authorizes Brandon Fenn of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brandon Fenn of Cooley LLP at (212) 479-6626.

*[Signature page follows]*

---

Very truly yours,

VectivBio Holding AG

By: /s/ Luca Santarelli  
Luca Santarelli  
*Chief Executive Officer*

---

cc: Scott Applebaum, VectivBio Holding AG  
Brandon Fenn, Cooley LLP  
Dayne Brown, Cooley LLP  
Andreas Müller, Homburger AG